{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:20:56Z","timestamp":1785410456487,"version":"3.56.0"},"reference-count":82,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arrhythm Electrophysiol Rev"],"abstract":"<jats:p>The management of AF in patients with heart failure is complex and nuanced. This paper explores the potential antiarrhythmic effects of guideline-directed medical therapy for heart failure and reviews the pharmacological and ablative treatments for AF. Heart failure with reduced ejection fraction is discussed separately from heart failure with preserved ejection fraction. Treatment recommendations for each heart failure subtype are given.<\/jats:p>","DOI":"10.15420\/aer.2025.39","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:17:38Z","timestamp":1777893458000},"source":"Crossref","is-referenced-by-count":0,"title":["Which Patient Benefits from Guideline-directed Medical Therapy for Heart Failure and Rate Control versus Rhythm Control in Patients with Congestive Heart Failure and Atrial Fibrillation and What are Those Therapies?"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7415-0288","authenticated-orcid":false,"given":"Gregory","family":"Burkman","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01h22ap11","id-type":"ROR","asserted-by":"publisher"}],"name":"Penn State Milton S. Hershey Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4554","authenticated-orcid":false,"given":"Gerald V","family":"Naccarelli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01h22ap11","id-type":"ROR","asserted-by":"publisher"}],"name":"Penn State Milton S. Hershey Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016;133:484\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018614; PMID: 26746177.","DOI":"10.1161\/CIRCULATIONAHA.115.018614"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920\u20135. https:\/\/doi.org\/10.1161\/01.CIR.0000072767.89944.6E; PMID: 12771006.","DOI":"10.1161\/01.CIR.0000072767.89944.6E"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D\u20138D. https:\/\/doi.org\/10.1016\/S0002-9149(02)03373-8; PMID: 12670636.","DOI":"10.1016\/S0002-9149(02)03373-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003;107:1291\u20136. https:\/\/doi.org\/10.1161\/01.CIR.0000054611.89228.92; PMID: 12628950.","DOI":"10.1161\/01.CIR.0000054611.89228.92"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548\u201357. https:\/\/doi.org\/10.1016\/j.ahj.2004.09.033; PMID: 15864246.","DOI":"10.1016\/j.ahj.2004.09.033"},{"key":"ref5","unstructured":"Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) Program. Am Heart J 2006;151:985\u201391. https:\/\/doi.org\/10.1016\/j.ahj.2005.06.036; PMID: 16644318."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program. J Am Coll Cardiol 2006;47:1997\u20132004. https:\/\/doi.org\/10.1016\/j.jacc.2006.01.060; PMID: 16697316.","DOI":"10.1016\/j.jacc.2006.01.060"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26\u201335. https:\/\/doi.org\/10.1093\/eurheartj\/ehx564; PMID: 29040525.","DOI":"10.1093\/eurheartj\/ehx564"},{"key":"ref8","unstructured":"Swedberg K, Zannad F, McMurray JJV, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012;59:1598\u2013603. https:\/\/doi.org\/10.1016\/j.jacc.2011.11.063; PMID: 22538330."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Myhre PL, Vaduganathan M, Claggett B, et al. B-type natriuretic peptide during treatment with Sacubitril\/Valsartan: the PARADIGM-HF trial. J Am Coll Cardiol 2019;73:1264\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.018; PMID: 30846338.","DOI":"10.1016\/S0735-1097(19)33679-4"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Olsson LG, Swedberg K, Cleland JGF, et al. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol or Metoprolol European Trial (COMET) trial. Eur J Heart Fail 2007;9:795\u2013801. https:\/\/doi.org\/10.1016\/j.ejheart.2007.07.010; PMID: 17693380.","DOI":"10.1016\/j.ejheart.2007.07.010"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008;52:997\u20131003. https:\/\/doi.org\/10.1016\/j.jacc.2008.04.069; PMID: 18786480.","DOI":"10.1016\/j.jacc.2008.04.069"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Shin DI, Jaekel K, Schley P, et al. Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion. Z Kardiol 2005;94:795\u2013800. https:\/\/doi.org\/10.1007\/s00392-005-0301-7; PMID: 16382379.","DOI":"10.1007\/s00392-005-0301-7"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Solheim E, Off MK, Hoff PI, et al. N-terminal pro-B-type natriuretic peptide level at long-term follow-up after atrial fibrillation ablation: a marker of reverse atrial remodelling and successful ablation. J Interv Card Electrophysiol 2012;34:129\u201336. https:\/\/doi.org\/10.1007\/s10840-011-9629-2; PMID: 21993599.","DOI":"10.1007\/s10840-011-9629-2"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Mogensen UM, Jhund PS, Abraham WT, et al. Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2017;70:2490\u2013500. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.027; PMID: 29145948.","DOI":"10.1016\/j.jacc.2017.09.027"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Zafrir B, Lund LH, Laroche C, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14\u2009964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J 2018;39:4277\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehy626; PMID: 30325423.","DOI":"10.1093\/eurheartj\/ehy626"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Huang W, Nurhafizah A, Frederich A, et al. Risk and protective factors of poor clinical outcomes in heart failure with improved ejection fraction population: a systematic review and meta-analysis. Curr Cardiol Rep 2025;27:4. https:\/\/doi.org\/10.1007\/s11886-024-02180-w; PMID: 39760806.","DOI":"10.1007\/s11886-024-02180-w"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Schach C, K\u00f6rtl T, Zeman F, et al. Clinical characterization of arrhythmia-induced cardiomyopathy in patients with tachyarrhythmia and idiopathic heart failure. JACC Clin Electrophysiol 2024;10:870\u201381. https:\/\/doi.org\/10.1016\/j.jacep.2024.102332; PMID: 38483417.","DOI":"10.1016\/j.jacep.2024.102332"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Aoyama D, Miyazaki S, Amaya N, et al. Treatment with catheter ablation for patients with arrhythmia-induced cardiomyopathy caused by atrial fibrillation promises a good prognosis. Heart Vessels 2024;39:240\u201351. https:\/\/doi.org\/10.1007\/s00380-023-02329-7; PMID: 37872308.","DOI":"10.1007\/s00380-023-02329-7"},{"key":"ref19","unstructured":"Newman JD, O\u2019Meara E, B\u00f6hm M, et al. Implications of atrial fibrillation for guideline-directed therapy in patients with heart failure: JACC State-of-the-Art Review. J Am Coll Cardiol 2024;83:932\u201350. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.033; PMID: 38418008."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Gopinathannair R, Chen LY, Chung MK, et al. Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: a scientific statement from the American Heart Association. Circ Arrhythm Electrophysiol 2021;14:HAE0000000000000078. https:\/\/doi.org\/10.1161\/HAE.0000000000000078; PMID: 34129347.","DOI":"10.1161\/HAE.0000000000000080"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2023;149:e1\u2013e156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193; PMID: 38033089.","DOI":"10.1161\/CIR.0000000000001207"},{"key":"ref22","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45:3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176; PMID: 39210723."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1707855; PMID: 29385358.","DOI":"10.1056\/NEJMoa1707855"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Noseworthy PA, Van Houten HK, Gersh BJ, et al. Generalizability of the CASTLE-AF trial: catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm 2020;17:1057\u201365. https:\/\/doi.org\/10.1016\/j.hrthm.2020.02.030; PMID: 32145348.","DOI":"10.1016\/j.hrthm.2020.02.030"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Noseworthy PA, Gersh BJ, Kent DM, et al. Atrial fibrillation ablation in practice: assessing CABANA generalizability. Eur Heart J 2019;40:1257\u201364. https:\/\/doi.org\/10.1093\/eurheartj\/ehz085; PMID: 30875424.","DOI":"10.1093\/eurheartj\/ehz085"},{"key":"ref26","unstructured":"Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016;133:1637\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.019406; PMID: 27029350."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Pasqualotto E, Ternes CMP, Chavez MP, et al. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction patients: a meta-analysis. Heart Rhythm 2024;21:1604\u201312. https:\/\/doi.org\/10.1016\/j.hrthm.2024.04.098; PMID: 38705438.","DOI":"10.1016\/j.hrthm.2024.04.098"},{"key":"ref28","unstructured":"Sohns C, Fox H, Marrouche NF, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med 2023;389:1380\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2306037; PMID: 37634135."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zheng Y, He W, et al. Efficacy of catheter ablation for atrial fibrillation in heart failure: a meta-analysis of randomized controlled trials. ESC Heart Fail 2024;11:2684\u201393. https:\/\/doi.org\/10.1002\/ehf2.14814; PMID: 38661235.","DOI":"10.1002\/ehf2.14814"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Pan KL, Wu YL, Lee M, Ovbiagele B. Catheter ablation compared with medical therapy for atrial fibrillation with heart failure: a systematic review and meta-analysis of randomized controlled trials. Int J Med Sci 2021;18:1325\u201331. https:\/\/doi.org\/10.7150\/ijms.52257; PMID: 33628087.","DOI":"10.7150\/ijms.52257"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Ahluwalia N, Hussain A, Providencia R, Schilling RJ. Predictors of improvement in left ventricular systolic dysfunction in patients with atrial fibrillation undergoing catheter ablation: systematic review. Arrhythm Electrophysiol Rev 2025;14:e02. https:\/\/doi.org\/10.15420\/aer.2024.24; PMID: 40017669.","DOI":"10.15420\/aer.2024.24"},{"key":"ref32","unstructured":"Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1261\u201374. https:\/\/doi.org\/10.1001\/jama.2019.0693; PMID: 30874766."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation 2021;143:1377\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050991; PMID: 33554614.","DOI":"10.1161\/CIRCULATIONAHA.120.050991"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 1991;324:781\u20138. https:\/\/doi.org\/10.1056\/NEJM199103213241201; PMID: 1900101.","DOI":"10.1056\/NEJM199103213241201"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"K\u00f8ber L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678\u201387. https:\/\/doi.org\/10.1056\/NEJMoa0800456; PMID: 18565860.","DOI":"10.1056\/NEJMoa0800456"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol. Lancet 1996;348:7\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(96)02149-6; PMID: 8691967.","DOI":"10.1016\/S0140-6736(96)02149-6"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998;98:2574\u20139. https:\/\/doi.org\/10.1161\/01.CIR.98.23.2574; PMID: 9843465.","DOI":"10.1161\/01.CIR.98.23.2574"},{"key":"ref38","unstructured":"Torp-Pedersen C, M\u00f8ller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857\u201365. https:\/\/doi.org\/10.1056\/NEJM199909163411201; PMID: 10486417."},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001;104:292\u20136. https:\/\/doi.org\/10.1161\/01.CIR.104.3.292; PMID: 11457747.","DOI":"10.1161\/01.CIR.104.3.292"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Hagens VE, Crijns HJGM, Van Veldhuisen DJ, et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 2005;149:1106\u201311. https:\/\/doi.org\/10.1016\/j.ahj.2004.11.030; PMID: 15976795.","DOI":"10.1016\/j.ahj.2004.11.030"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"McMurray J, K\u00f8ber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005;45:525\u201330. https:\/\/doi.org\/10.1016\/j.jacc.2004.09.076; PMID: 15708698.","DOI":"10.1016\/j.accreview.2005.05.018"},{"key":"ref42","unstructured":"Kotecha D, Flather MD, Altman DG, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol 2017;69:2885\u201396. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.001; PMID: 28467883."},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013;1:21\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2012.09.002; PMID: 24621795.","DOI":"10.1016\/j.jchf.2012.09.002"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Cadrin-Tourigny J, Shohoudi A, Roy D, et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an AF-CHF substudy. JACC Heart Fail 2017;5:99\u2013106. https:\/\/doi.org\/10.1016\/j.jchf.2016.10.015; PMID: 28089316.","DOI":"10.1016\/j.jchf.2016.10.015"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001;142:498\u2013501. https:\/\/doi.org\/10.1067\/mhj.2001.117318; PMID: 11526364.","DOI":"10.1067\/mhj.2001.117318"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525\u201333. https:\/\/doi.org\/10.1056\/NEJM199702203360801; PMID: 9036306.","DOI":"10.1056\/NEJM199702203360801"},{"key":"ref47","unstructured":"Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268\u201376. https:\/\/doi.org\/10.1056\/NEJMoa1109867; PMID: 22082198."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Ganesan AN, Brooks AG, Roberts-Thomson KC, et al. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure: a systematic review. J Am Coll Cardiol 2012;59:719\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2011.10.891; PMID: 22340263.","DOI":"10.1016\/j.jacc.2011.10.891"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Khan MN, Ja\u00efs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008;359:1778\u201385. https:\/\/doi.org\/10.1056\/NEJMoa0708234; PMID: 18946063.","DOI":"10.1056\/NEJMoa0708234"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063; PMID: 35363499.","DOI":"10.1161\/CIR.0000000000001073"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376\u201380. https:\/\/doi.org\/10.1161\/01.CIR.100.4.376; PMID: 10421597.","DOI":"10.1161\/01.CIR.100.4.376"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Mohammad Z, Ahmad J, Sultan A, et al. Effect of sacubitril-valsartan on the incidence of atrial fibrillation: a meta-analysis. J Cardiovasc Electrophysiol 2023;34:1037\u201342. https:\/\/doi.org\/10.1111\/jce.15880; PMID: 36871177.","DOI":"10.1111\/jce.15880"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Cikes M, Planinc I, Claggett B, et al. Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC Heart Fail 2022;10:336\u201346. https:\/\/doi.org\/10.1016\/j.jchf.2022.01.018; PMID: 35483796.","DOI":"10.1016\/j.jchf.2022.01.018"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Neefs J, van den Berg NWE, Krul SPJ, et al. Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. Am J Cardiovasc Drugs 2020;20:73\u201380. https:\/\/doi.org\/10.1007\/s40256-019-00353-5; PMID: 31214914.","DOI":"10.1007\/s40256-019-00353-5"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389; PMID: 30415602.","DOI":"10.1056\/NEJMoa1812389"},{"key":"ref56","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303; PMID: 31535829."},{"key":"ref57","unstructured":"Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667\u201377. https:\/\/doi.org\/10.1056\/NEJMoa0708789; PMID: 18565859."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924\u201330. https:\/\/doi.org\/10.1136\/hrt.2008.158931; PMID: 19282313.","DOI":"10.1136\/hrt.2008.158931"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Talajic M, Khairy P, Levesque S, et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol 2010;55:1796\u2013802. https:\/\/doi.org\/10.1016\/j.jacc.2010.01.023; PMID: 20413028.","DOI":"10.1016\/j.jacc.2010.01.023"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Burkman G, Naccarelli GV. Rhythm control of atrial fibrillation in heart failure with reduced ejection fraction. Curr Cardiol Rep 2020;22:83. https:\/\/doi.org\/10.1007\/s11886-020-01336-8; PMID: 32647927.","DOI":"10.1007\/s11886-020-01336-8"},{"key":"ref61","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038; PMID: 34449189."},{"key":"ref62","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286; PMID: 36027570."},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Filippatos G, Farmakis D, Butler J, et al. Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. Eur J Heart Fail 2023;25:970\u20137. https:\/\/doi.org\/10.1002\/ejhf.2861; PMID: 37062866.","DOI":"10.1002\/ejhf.2861"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Butt JH, Kondo T, Jhund PS, et al. Atrial fibrillation and dapagliflozin efficacy in patients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2022;80:1705\u201317. https:\/\/doi.org\/10.1016\/j.jacc.2022.08.718; PMID: 36041668.","DOI":"10.1016\/j.jacc.2022.08.718"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Cikes M, Claggett B, Shah AM, et al. Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial. JACC Heart Fail 2018;6:689\u201397. https:\/\/doi.org\/10.1016\/j.jchf.2018.05.005; PMID: 30007557.","DOI":"10.1016\/j.jchf.2018.05.005"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Naccarelli GV, Filippone EJ, Foy A. Do mineralocorticoid receptor antagonists suppress atrial fibrillation\/flutter? J Am Coll Cardiol 2021;78:153\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.080; PMID: 34015479.","DOI":"10.1016\/j.jacc.2021.04.080"},{"key":"ref67","unstructured":"Parkash R, Wells GA, Rouleau J, et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial. Circulation 2022;145:1693\u2013704. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057095; PMID: 35313733."},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Chieng D, Sugumar H, Segan L, et al. Atrial fibrillation ablation for heart failure with preserved ejection fraction: a randomized controlled trial. JACC Heart Fail 2023;11:646\u201358. https:\/\/doi.org\/10.1016\/j.jchf.2023.01.008; PMID: 36868916.","DOI":"10.1016\/j.jchf.2023.01.008"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Martens P, Augusto SN Jr, Erzeel J, et al. Effects of atrial fibrillation ablation for heart failure with preserved ejection fraction: insights from CABANA. JACC Heart Fail 2025;13:785\u201394. https:\/\/doi.org\/10.1016\/j.jchf.2025.01.029; PMID: 40243977.","DOI":"10.1016\/j.jchf.2025.01.029"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2019422; PMID: 32865375.","DOI":"10.1056\/NEJMoa2019422"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation 2021;144:845\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056323; PMID: 34328366.","DOI":"10.1161\/CIRCULATIONAHA.121.056323"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Bulh\u00f5es E, Antunes VLJ, Mazetto R, et al. Catheter ablation versus medical therapy for atrial fibrillation in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Rhythm 2024;21:1595\u2013603. https:\/\/doi.org\/10.1016\/j.hrthm.2024.04.058; PMID: 38621498.","DOI":"10.1016\/j.hrthm.2024.04.058"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Mahalleh M, Soleimani H, Pazoki M, et al. Heart failure with preserved ejection fraction and atrial fibrillation: catheter ablation vs. standard medical therapy \u2013 a systematic review and meta-analysis. Heart Fail Rev 2025;30:1\u201315. https:\/\/doi.org\/10.1007\/s10741-024-10437-3; PMID: 39278992.","DOI":"10.1007\/s10741-024-10437-3"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Xie Z, Qi B, Wang Z, et al. Ablation for atrial fibrillation improves the outcomes in patients with heart failure with preserved ejection fraction. Europace 2023;26:euad363. https:\/\/doi.org\/10.1093\/europace\/euad363; PMID: 38099508.","DOI":"10.1093\/europace\/euad363"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Johner N, Namdar M, Shah DC. Safety, efficacy and prognostic benefit of atrial fibrillation ablation in heart failure with preserved ejection fraction. Arrhythm Electrophysiol Rev 2022;11:e18. https:\/\/doi.org\/10.15420\/aer.2022.10; PMID: 36304203.","DOI":"10.15420\/aer.2022.10"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Piccini JP, Camm AJ, et al. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial. Eur J Heart Fail 2022;24:1094\u2013101. https:\/\/doi.org\/10.1002\/ejhf.2487; PMID: 35293087.","DOI":"10.1002\/ejhf.2487"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Fauchier L, Bisson A, Bodin A. Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions. BMC Med 2023;21:54. https:\/\/doi.org\/10.1186\/s12916-023-02764-3; PMID: 36782248.","DOI":"10.1186\/s12916-023-02764-3"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart 2011;97:740\u20137. https:\/\/doi.org\/10.1136\/hrt.2010.207340; PMID: 21051458.","DOI":"10.1136\/hrt.2010.207340"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61:1894\u2013903. https:\/\/doi.org\/10.1016\/j.jacc.2013.01.069; PMID: 23500267.","DOI":"10.1016\/j.jacc.2013.01.069"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014;7:31\u20138. https:\/\/doi.org\/10.1161\/CIRCEP.113.000806; PMID: 24382410.","DOI":"10.1161\/CIRCEP.113.000806"},{"key":"ref81","unstructured":"Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol 2017;70:1949\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.041; PMID: 28855115."}],"container-title":["Arrhythmia &amp; Electrophysiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.aerjournal.com\/articleindex\/aer.2025.39","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:18:25Z","timestamp":1777893505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerjournal.com\/articleindex\/aer.2025.39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":82,"URL":"https:\/\/doi.org\/10.15420\/aer.2025.39","relation":{},"ISSN":["2050-3369","2050-3377"],"issn-type":[{"value":"2050-3369","type":"print"},{"value":"2050-3377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"article-number":"e17"}}